SCHEMBL17848762

SCHEMBL17848762

CS(=O)(=O)c1ccccc1CCO

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.42
ADRA1A P35348 3/20 0.39
ADRA1D P25100 3/20 0.39
ADRA1B P35368 2/20 0.39
SLC6A2 P23975 1/20 0.39
BCAT2 O15382 1/20 0.39
TDP1 Q9NUW8 1/20 0.37
CTSB P07858 1/20 0.36
LOX P28300 1/20 0.36
PTPN1 P18031 1/20 0.36
NR1H2 P55055 2/20 0.35
NR1H3 Q13133 2/20 0.35
DRD2 P14416 1/20 0.35
MPO P05164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5663968 0.89 ADRA1D (0.41) MEN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL5146232 0.83 MMP2 (0.42) MEN1CYP2D6KMT2ATDP1CTSB
SCHEMBL30569427 0.83 CYP2D6 (0.45) MEN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL506623 0.83 CYP2D6 (0.45) MEN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL10181521 0.82 DRD2 (0.42) MEN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL1807545 0.82 MYC (0.43) CYP1A2CYP2D6TDP1CTSBPTPN1
SCHEMBL3845969 0.81 MEN1 (0.40) MEN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL27339143 0.80 ADRA1D (0.49) MEN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL7145103 0.80 ADRA1D (0.39) MEN1CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL10865912 0.80 MYC (0.42) CYP1A2CYP2D6TDP1CTSBPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233077-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2026-05-06 EP disclosed
US-12428373-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2025-09-30 US disclosed
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2023-05-11 US disclosed
US-11498896-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2022-11-15 US disclosed
US-20210147355-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2021-05-20 US disclosed
US-20210040062-A1 AZOLE-SUBSTITUTED PYRIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2021-02-11 US disclosed
US-20210040062-A1 AZOLE-SUBSTITUTED PYRIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2021-02-11 US disclosed
US-10633336-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2020-04-28 US disclosed
EP-3418276-A1 AZOLE-SUBSTITUTED PYRIDINE COMPOUND Taisho Pharmaceutical Co., Ltd. (JP) 2018-12-26 EP disclosed
US-20180155283-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2018-06-07 US disclosed
EP-3233077-A1 DOPAMINE D2 RECEPTOR LIGANDS The Broad Institute Inc. (US) 2017-10-25 EP disclosed
WO-2017141927-A1 AZOLE-SUBSTITUTED PYRIDINE COMPOUND 大正製薬株式会社 2017-08-24 WO disclosed
WO-2016100940-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155283-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, DRD3, ARRB1 MEN1 4669/4885CYP1A2 3044/4885CYP3A4 4575/4885
US-11498896-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 MEN1 4490/4885CYP1A2 1871/4885CYP3A4 3886/4885
US-10633336-B2 Dopamine D2 receptor ligands DRD2, ARRB1, DRD3 MEN1 4583/4885CYP1A2 2904/4885CYP3A4 4322/4885
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 MEN1 4490/4885CYP1A2 1871/4885CYP3A4 3886/4885
US-20210147355-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 MEN1 4490/4885CYP1A2 1871/4885CYP3A4 3886/4885
US-12428373-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 MEN1 4490/4885CYP1A2 1871/4885CYP3A4 3886/4885
US-20210040062-A1 AZOLE-SUBSTITUTED PYRIDINE COMPOUND CYP2F1, CYP21A2, CYP11B1 MEN1 2338/4885CYP1A2 41/4885CYP3A4 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.